CURAXYS is a European biopharmaceutical company specialized in the research, development, production and commercialization of therapeutical proteins of high added technological value thanks to its own technology which covers from gene translation to the industrial protein production.


CURAXYS is currently the only company in Spain that is integrated from bench to production and commercialization of biosimilars, among other therapeutic proteins. Regarding the development of new products, it is reckoned to be the sixth on a worldwide scale, according to “Data Monitor” (published Feb. 2012).

Curaxys´ staff is integrated by 22 people. 90% of them are exclusively devoted to R&D&I and 17 of them were hired through the INNCORPORA TU, FPGS, and Torres Quevedo programmes, who specialise in the recruitment of qualified staff.


More on Curaxys
We focus on the research, production and commercialization of recombinant proteins added value through the utilization of CuraMab® with specific human cell lines
Our expression system allows us to reach of recombinant protein levels that are clearly above those currently available.
We developed a downstream technological platform on the basis of our own laboratory data.

Latest News

  • Curaxys obtains financing for the purchase of equipment with the help granted by Innplanta 2012
  • Curaxys hires five more technologists.
  • One of the largest biopharmaceutical projects in Europe to be started at Tecnobahía.
  • Innovaxis, a novel company for “custom medicine”
  • Strategic Alliance for cancer disease
  • UCA and Curaxys create a Cathedra in biopharmaceuticals in order to research biosimilar proteins
  • Curaxys is ranked among the world top ten companies in the research of biologic generic medicines

  • Copyright 2012 Curaxys. All Rights Reserved
    Legal Advice